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Abstract
Immunity, based on a natural and an educated system, is responsible for recognition and elimination
of infectious particles, cellular waste, modified self and transformed cells. This dual system
guarantees that dangerous particles are removed immediately after appearance and that a memory
with maturated weapons exists, if the organism is re-infected by the same particle. For malignant
cells, however, the immune response seems to be restricted to innate immunity, because at least
for the humoral response, all so far detected tumor-specific antibodies belong to the natural
immunity. In this review we try to explain why malignant cells might be "too sweet" to induce a
memory.
Immunity
Innate or natural immunity is an inherited defense sys-
tem, which removes dangerous bacteria, fungi, modified
self (e.g. oxidized molecules), secreted molecules, waste
and transformed cells at a very early stage [1,2]. The innate
response is invariable and works by using a transmitted
germ-line coded pool of specific receptors [3-5]. These
receptors are expressed on NK cells, γδ-T-cells and macro-
phages which cover a broad spectrum of different antigens
[6-8]. They belong to a recently discovered family of pat-
tern recognition receptors which show homology with the
Drosophila Toll protein and the human interleukin-1
receptor family [3]. These Toll-like receptors (TLRs) don't
recognize specific single structures, but specific patterns,
termed pathogen-associated molecular patterns, like car-
bohydrates on glycoproteins and glycolipids and repeti-
tive structures which are shared by different molecules
and even organisms (e.g. LPS) [9,10]. This non-protein
binding has another advantage, i.e. immunity does not
need to follow all mutational changes, which are com-
monly observed for proteins. The recognition of non-self
structures is, in contrast to the acquired immunity, T-cell
and MHC independent.
Based on the pioneering work of Jan Klein and Barju Ben-
acerraf in the early 70th, the dual recognition system was
accepted as the crucial mechanism for the induction of
acquired immunity [11,12]. Non-self proteins are gener-
ally taken up by phagocytic cells, digested by proteases
and presented as protein-fragments, peptides or motifs to
immuno-competent cells [13]. The H-2 complex in mice
and the MHC system in humans code for molecules
which serve as co-receptors and which are presented
together with the foreign peptide [11,14,15]. This leads to
an activation of T-cells and affinity maturation of effector
and memory cells and creates highly specific and high aff-
ine antibodies and receptors on T-cells. Only MHC with
non-self triggers a maturation and a memory and only
proteins, but not carbohydrate structures can be presented
as non-self (Fig. 1).
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In humans, malignancy can be considered as a chronic
disease. Based on the simple calculation of the number of
cells and the spontaneous mutation rate, cellular transfor-
mation is a common and frequent process and only the
manifest tumors are rare events. A very efficient cellular
repair mechanism and immuno-competent cells and
mechanisms (immuno-surveillance) keep the number of
growing tumors at a very low level. However, an immune
response needs targets, molecules which are specifically
expressed on malignant cells and absent on normal cells
and tissue [5]. Over the years an enormous amount of
data has accumulated clearly showing that tumor-specific
epitopes associated with malignant transformation are
carbohydrate modifications [16].
Serum sugars
Sugars (oligosaccharides and polysaccharides) existing
either in free form or in covalent complexes with proteins
or lipids are found on all cells in an organism. These gly-
cans are either membrane-associated and form the glyco-
type of a cell or are secreted. Malignant cells very often
The natural immunity is the first actor on stage in immune surveillance processesFigure 1
The natural immunity is the first actor on stage in immune surveillance processes. With an inherited set of pattern recognition 
receptors on NK cells and with natural IgM antibodies it recognizes and destroys all invasive particles and all changes and mod-
ifications within an organism. Their targets are often conservative structures, in most cases carbohydrates. Phagocytic cells 
clean "the battle field" and transport the garbage to nearby lymphoid organs. Here, the decision is made whether a memory 
should be initiated or not. In cases of infectious particles, immunocompetent Th cells (T-helper cells) are stimulated by pre-
senting to them non-self (viral) protein peptides together with self structures (MHC). In consequence highly specific Tk (T-
killer cells) and B2 cells are generated. In case of cancer cells and carbo-epitopes, this dual recognition fails, because the phago-
cytic cells cannot present carbohydrat structures originally seen by the innate immunity. Peptides which are associated with 
carbohydrate structures are "self" structures and therefore, an education and memory does normally not occur.Page 2 of 5
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urement of certain glycan levels can be used to facilitate
diagnosis, track tumor recurrence or tumor burden or pro-
vide a surrogate measure for therapeutic response. For
example, the serological markers CA125, CA19-9 and
CA15-3 are mucin glycoconjugates commonly over-
expressed by ovarian, pancreatic and breast adenocarcino-
mas, respectively, and their serum levels correlate with
tumor burden and prognosis [17,18]. CA19-9 is the
epitope which interacts with SLeA on pancreatic carci-
noma mucins [19] and its expression facilitates selectin-
mediated adhesion during haematogenous metastasis. In
breast cancer, the tumor antigen CA15-3 is expressed on
MUC1, which is aberrantly expressed in more than 90%
of breast carcinomas and appears to promote invasion
[20]. Therefore, the glycans CA125, CA19-9 and CA15-3
are examples of molecules that not only serve as tumor
markers for diagnosis, but also appear to serve as impor-
tant patho-physiological factors in cancer progression
[21].
Membrane sugars
Membrane bound carbohydrate antigens can be catego-
rized into two major groups: (i) glycolipids such as GM2,
GD2, GD3, and fucosyl GM1 (gangliosides), and Lewisy
(Ley) and globo H (neutral glycolipids); and (ii) glycopro-
teins such as the mucin-related epitopes Tn (GalNAcα-O-
Ser/Thr), TF (Thomsen-Friedenreich, Galβ1→3GalNAcα-
O-Ser/Thr) and STn (NeuAcα2→6GalNAcα-O-Ser/Thr).
Gangliosides modulate transmembrane signaling essen-
tial for tumor cell growth, invasion, and metastasis. GM2,
GD2, GD3 are the major gangliosides expressed on most
human cancers of neuro-ectodermal and epithelial origin
[22]. In melanoma cells the ganglioside composition has
been found to correlate with their metastatic potential
and also to be selectively expressed in cells of a tumor
mass and invading tumor cells [23]. Gangliosides have
shown to be negatively correlated with survival. In
melanoma naturally occurring antibodies to the ganglio-
side GM2 have been shown to correlate with improved
survival. Lewis(y) (Le(y), also designated CD174, repre-
sents a carbohydrate blood group antigen which is
strongly expressed in neoplastic gastrointestinal tissues. It
has procoagulant and angiogenic activities [24].
The cell-surface glycosphingolipid Globo H is another
member of a family of antigenic carbohydrates that are
highly expressed on the cell surface of prostate, ovarian
cancers and breast cancer cells. Furthermore, it has been
established that the serum of breast cancer patients con-
tains high levels of antibodies against the Globo H
epitope [25].
The second group of membrane bound carbohydrate anti-
gens are glycoproteins. There are several examples of spe-
cific glycoproteins undergoing changes in glycosylation
upon malignant transformation, which exist in mem-
brane-bound forms. Abnormal expression of the mucins
MUC1 and MUC4 has been observed in tumor cells of
various tissues, including lung, colon, pancreatic, ovarian,
and breast cancers. Truncation of the O-glycans in cancer
cells leads to the appearance of another novel carbohy-
drate epitopes, such as Thomas Friedrich (TF), Tn and sia-
lyl Tn antigens [26].
Another group of membrane bound structures with mod-
ified glycosylation patterns on cancer cells are heat shock
proteins. Heat shock proteins are known as chaperones
which are involved in folding or maturation of proteins,
transport out of the cell and signaling pathways [27,28]
but they are characteristically over-expressed and modi-
fied in and on the surface of malignant transformed cells
[29-31]. Over-expression of these chaperones obviously
implicates a higher drug resistance and a greater degree of
malignancy and is often associated with bad prognosis
[32,33]. The glucose-regulated protein 78 kDa (GRP78) is
a member of the heat shock protein 70 kDa (HSP70) fam-
ily. High levels of cell surface-associated GRP78 are
detected on a variety of carcinoma cells, such as breast
cancer hepatocellular, and prostate cancers [33]. Recent
studies show that GRP78 is expressed on tumor cells with
a post-transcriptionally modified glycosylation [34].
Additionally, cell protection molecules and growth factor
receptors are affected by tumor specific altered glycosyla-
tion.
The decay acceleration factor (DAF, also named CD55) is
a cell surface molecule which prevents cell lysis by autol-
ogous complement. A modified isoform of CD55 is exclu-
sively expressed on the membrane of stomach carcinoma
cells. This modified molecule (CD55/SC-1) is co-
expressed with the wild-type of CD55 on the cancer cell
surface [35].
Growth factor receptors are often over-expressed on
malignant cells as well. CFR-1 (cysteine-rich fibroblast
growth factor receptor) is an integral membrane glycopro-
tein which is expressed in an post-transcriptionally modi-
fied version on almost all epithelial cancers of every type
and origin and on precursor stages, but not on healthy tis-
sues [36,37]. Again the modification is found in the car-
bohydrate structure of the molecule [36].
Immunity to sugars
Antibodies and NK cells against several carbohydrate anti-
gens have been detected in sera of cancer patients and
patients treated with cancer vaccines, and have been asso-Page 3 of 5
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been detected in experimental systems binding to LewisX
oligosaccharides on melanoma cells and having tumor-
suppressive effects [39]. NK cells detecting the heparan
sulfate moieties of membranal heparan sulfate proteogly-
cans (HSPGs) are able to lyse tumor cells [40].
Dendritic cells have been reported to react with colorectal
cancer cells. This interaction is mediated through binding
of Lewis(x) and Lewis(y) carbohydrates on CEA of color-
ectal cancer cells. In contrast, dendrites do not bind CEA
expressed on normal colon epithelium containing low
levels of Lewis antigens. This indicates that dendritic cells
may recognize colorectal cancer cells through binding to
tumor-specific glycosylation on CEA [41].
Furthermore, carbohydrates can be used as anti-cancer
vaccines and patients develop a measurable antibody
response [42,43]. Interestingly, modified carbohydrates
like GD2 and GD3 lactones and N-propionylated poly-
sialic acid were significantly more effective in inducing
antibodies against tumor cells than the unmodified anti-
gens. Tn, sTn and TF trimers (clusters) were significantly
more effective than the monomers in inducing antibodies
reacting with the cancer cell surface [38,42]. Patients vac-
cinated with tumor surface GD2 developed a significant
IgM level, however, reactivity of vaccine-induced IgG anti-
bodies against GD2 on the tumor cell surface could not be
demonstrated in any patient [44].
In patients vaccinated with globo H-keyhole limpet
hemocyanin vaccine a broad polyclonal antibody activity
could be measured [45]. Here a significant IgG level could
be detected in active sera, and the authors claim a class
switch from IgM to IgG. However it could not be demon-
strated that the IgG antibodies alone are responsible for
the anti-vaccine activity [43].
In addition, a broad study on the humoral immunity of
cancer patients revealed, that all cancer specific antibodies
were germ-line coded IgMs, member of the natural immu-
nity. Over 80% of these monoclonal antibodies were
expressed by VH genes of the VH3 gene family. Within
this family especially the germ-line genes DP47 and DP49
were overrepresented. Genetic restriction is not unique to
heavy chain genes, it is also found within VL genes. More
than 90% of the monoclonal antibodies isolated from
cancer patients utilized λ-light chain genes [5,46]. Most
interestingly, all investigated IgM antibodies detect carbo-
hydrate epitopes on post-transcriptionally modified cell
surface receptors [5,35,36]. The human monoclonal anti-
body SC-1, which was isolated from a patient with a signet
ring cell carcinoma of the stomach, reacts with a N-linked
carbohydrate epitope present on an isoform of DAF-B
(subsequently named DAFSC-1 with a molecular weight of
approx. 82 kDa [35]. Clinical studies have shown that spe-
cific induction of regression and apoptosis in primary
stomach cancers without any detected toxic cross-reactiv-
ity to normal tissue can be induced [47].
The human monoclonal antibody PAM-1 binds to a
tumor-specific N-linked carbohydrate epitope on CFR-1/
PAM-1 receptor, which is expressed on almost all epithe-
lial cancers of every type and origin and at precursor
stages, but not on healthy tissue [36,37]. PAM-1 inhibits
tumor growth in vitro and in animal systems, by inducing
apoptosis.
The human monoclonal antibody SAM-6 binds to a
tumor-specifc isoform of grp78, a member of the hsp70
family. The epitope is an O-linked carbohydrate [34].
SAM-6 induces in malignant cells a deadly concentration
of lipids, which ends in a specific form of apoptosis,
namely lipoptosis [48,49].
Conclusion
Malignant cells express and secrete tumor-specific carbo-
hydrate structures. These modified "non-self" sugars are
highly immunogenic and serve as targets for immune sur-
veillance mechanisms. Since only peptides can be pre-
sented together with "self" to immuno-competent T-cells,
no switch and education is induced and no memory is cre-
ated. This makes sense, because an immunological mem-
ory is only needed for infectious particles, which can hide
intracellulary and can re-infect. However, malignant cells
are neither infectious nor hide, and therefore, there is no
need for a memory. They really seem to "too sweet to
remember" for the immune system.
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